{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:47:04Z","timestamp":1767919624364,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007408","name":"Medical Center, University of Pittsburgh","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007408","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.neuropharm.2020.108241","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T21:05:44Z","timestamp":1595538344000},"page":"108241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Xie2-64, a novel CB2 receptor inverse agonist, reduces cocaine abuse-related behaviors in rodents"],"prefix":"10.1016","volume":"176","author":[{"given":"Chloe J.","family":"Jordan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Wei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Galaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Hua","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terence","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-Qun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng-Xiong","family":"Xi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2020.108241_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.brainres.2012.01.030","article-title":"The effects of cannabinoid CB1, CB2 and vanilloid TRPV1 receptor antagonists on cocaine addictive behavior in rats","volume":"1444","author":"Adamczyk","year":"2012","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108241_bib2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1476-5381.2010.00729.x","article-title":"CB2: a cannabinoid receptor with an identity crisis","volume":"160","author":"Atwood","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108241_bib3","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.bjp.0707303","article-title":"Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers","volume":"151","author":"Bingham","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108241_bib4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.bbr.2018.11.043","article-title":"Behavioral effects of psychostimulants in mutant mice with cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons","volume":"360","author":"Canseco-Alba","year":"2019","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108241_bib5","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1038\/nprot.2007.441","article-title":"Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation","volume":"2","author":"Carlezon","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.neuropharm.2020.108241_bib6","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1021\/acs.jcim.8b00623","article-title":"DAKB-GPCRs: an integrated computational platform for drug abuse related GPCRs","volume":"59","author":"Chen","year":"2019","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.neuropharm.2020.108241_bib7","first-page":"269","article-title":"Attenuation of cocaine-induced conditioned place preference and motor activity via cannabinoid CB2 receptor agonism and CB1 receptor antagonism in rats","volume":"20","author":"Delis","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108241_bib8","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1073\/pnas.1118167109","article-title":"Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors","volume":"109","author":"den Boon","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2020.108241_bib9","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3389\/fphar.2016.00370","article-title":"A personal retrospective: elevating anandamide (AEA) by targeting fatty acid amide hydrolase (FAAH) and the fatty acid binding proteins (FABPs)","volume":"7","author":"Deutsch","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108241_bib11","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.neuron.2016.08.017","article-title":"Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 receptor-dependent inhibition of dopamine release","volume":"91","author":"Foster","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2020.108241_bib12","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1038\/s41386-018-0231-5","article-title":"Deletion of the type 2 metabotropic glutamate receptor increases heroin abuse vulnerability in transgenic rats","volume":"43","author":"Gao","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108241_bib13","doi-asserted-by":"crossref","first-page":"107740","DOI":"10.1016\/j.neuropharm.2019.107740","article-title":"Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT1A and TRPV1 receptor mechanisms","volume":"167","author":"Galaj","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108241_bib14","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s40263-019-00664-w","article-title":"Potential of cannabinoid receptor ligands as treatment for substance use disorders","volume":"33","author":"Galaj","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2020.108241_bib15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bcp.2018.07.036","article-title":"Monoacylglycerol lipase (MAGL) as a promising therapeutic target","volume":"157","author":"Gil-Ordonez","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108241_bib16","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/bph.14473","article-title":"Opposing roles of CB1 and CB2 cannabinoid receptors in the stimulant and rewarding effects of cocaine","volume":"176","author":"Gobira","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108241_bib17","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/s41386-018-0050-8","article-title":"Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle","volume":"43","author":"Gonzalez-Cuevas","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108241_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0014-2999(97)01336-8","article-title":"Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals","volume":"339","author":"Griffin","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108241_bib19","doi-asserted-by":"crossref","first-page":"12315","DOI":"10.1038\/s41598-017-12399-z","article-title":"CB1 receptor activation on VgluT2-expressing glutamatergic neurons underlies delta(9)-tetrahydrocannabinol (Delta(9)-THC)-Induced aversive effects in mice","volume":"7","author":"Han","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2020.108241_bib20","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/bph.14969","article-title":"\u03b2-Caryophyllene, a dietary terpenoid, inhibits nicotine taking and nicotine seeking in rodents","volume":"177","author":"He","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108241_bib21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1006\/nbdi.1998.0215","article-title":"The CB1 cannabinoid receptor in the brain","volume":"5","author":"Howlett","year":"1998","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2020.108241_bib22","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1021\/acs.jcim.5b00739","article-title":"Difference and influence of inactive and active States of cannabinoid receptor subtype CB2: from conformation to drug discovery","volume":"56","author":"Hu","year":"2016","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.neuropharm.2020.108241_bib23","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1016\/S0968-0896(99)00219-9","article-title":"3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor","volume":"7","author":"Huffman","year":"1999","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108241_bib24","series-title":"State Estimates of Past Year Cocaine Use Among Adults: 2014 and 2015. The CBHSQ Report","author":"Hughes","year":"2016"},{"issue":"107609","key":"10.1016\/j.neuropharm.2020.108241_bib25","article-title":"Progress in agonist therapy for substance use disorders: lessons learned from methadone and buprenorphine","volume":"158","author":"Jordan","year":"2019","journal-title":"Neuropharmacology"},{"issue":"107597","key":"10.1016\/j.neuropharm.2020.108241_bib26","article-title":"The highly selective dopamine D3R antagonist, RVK4-40, attenuates oxycodone reward and augments analgesia in rodents","volume":"158","author":"Jordan","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108241_bib27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.neubiorev.2018.12.026","article-title":"Progress in brain cannabinoid CB2 receptor research: from genes to behavior","volume":"98","author":"Jordan","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2020.108241_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00213-013-3106-9","article-title":"Fenobam sulfate inhibits cocaine-taking and cocaine-seeking behavior in rats: implications for addiction treatment in humans","volume":"229","author":"Keck","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2020.108241_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881110367732","article-title":"Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis","volume":"25","author":"Lanciego","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108241_bib30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00213-009-1506-7","article-title":"The future of endocannabinoid-oriented clinical research after CB1 antagonists","volume":"205","author":"Le Foll","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2020.108241_bib31","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cell.2018.12.011","article-title":"Crystal structure of the human cannabinoid receptor CB2","volume":"176","author":"Li","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2020.108241_bib32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/hipo.22558","article-title":"Deletion of CB2 cannabinoid receptors reduces synaptic transmission and long-term potentiation in the mouse hippocampus","volume":"26","author":"Li","year":"2016","journal-title":"Hippocampus"},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108241_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/syn.22139","article-title":"D2 autoreceptor switches CB2 receptor effects on [3H]-dopamine release in the striatum","volume":"74","author":"L\u00f3pez-Ram\u00edrez","year":"2020","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2020.108241_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2020.108241_bib34","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/s41386-019-0366-z","article-title":"Translating the atypical dopamine uptake inhibitor hypothesis toward therapeutics for treatment of psychostimulant use disorders","volume":"44","author":"Newman","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108241_bib35","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S0022-3565(24)37266-0","article-title":"SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor","volume":"284","author":"Rinaldi-Carmona","year":"1998","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108241_bib36","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."},{"key":"10.1016\/j.neuropharm.2020.108241_bib37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.neuropharm.2017.05.031","article-title":"The endocannabinoid system as a target for addiction treatment: trials and tribulations","volume":"124","author":"Sloan","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108241_bib38","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3389\/fphar.2017.00720","article-title":"Cannabinoids modulate neuronal activity and cancer by CB1 and CB2 receptor-independent mechanisms","volume":"8","author":"Soderstrom","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108241_bib39","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2174\/1871527316666170413105421","article-title":"Neurological disorders in medical use of cannabis: an update","volume":"16","author":"Solimini","year":"2017","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"key":"10.1016\/j.neuropharm.2020.108241_bib40","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/bph.14625","article-title":"Cannabinoid CB1 and CB2 receptor mechanisms underlie cannabis reward and aversion in rats","volume":"176","author":"Spiller","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108241_bib41","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.neuron.2016.03.034","article-title":"Cannabinoid type 2 receptors mediate a cell type-specific plasticity in the Hippocampus","volume":"90","author":"Stempel","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2020.108241_bib42","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.neuropharm.2018.07.020","article-title":"Cannabinoid type 2 receptors mediate a cell type-specific self-inhibition in cortical neurons","volume":"139","author":"Stumpf","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108241_bib43","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1046\/j.1460-9568.2002.02041.x","article-title":"Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids","volume":"15","author":"Szabo","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108241_bib44","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1007\/s00018-016-2300-4","article-title":"The CB2 receptor and its role as a regulator of inflammation","volume":"73","author":"Turcotte","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.neuropharm.2020.108241_bib45","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.1115740","article-title":"Identification and functional characterization of brainstem cannabinoid CB2 receptors","volume":"310","author":"Van Sickle","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2020.108241_bib46","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.1523\/JNEUROSCI.0726-06.2006","article-title":"Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: role of glutamate in the nucleus accumbens","volume":"26","author":"Xi","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108241_bib47","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nn.2874","article-title":"Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice","volume":"14","author":"Xi","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108241_bib48","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cell.2020.01.007","article-title":"Cryo-EM structure of the human cannabinoid receptor CB2-gi signaling complex","volume":"180","author":"Xing","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2020.108241_bib49","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1021\/jm3017464","article-title":"Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation","volume":"56","author":"Yang","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108241_bib50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/sj.bjp.0706838","article-title":"In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?","volume":"149","author":"Yao","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108241_bib51","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/npp.2014.297","article-title":"Species differences in cannabinoid receptor 2 and receptor responses to cocaine self-administration in mice and rats","volume":"40","author":"Zhang","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108241_bib52","doi-asserted-by":"crossref","first-page":"E5007","DOI":"10.1073\/pnas.1413210111","article-title":"Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2020.108241_bib53","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.intimp.2011.04.013","article-title":"Mutagenesis and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand recognition and signal transduction for CB2 receptor","volume":"11","author":"Zhang","year":"2011","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.neuropharm.2020.108241_bib54","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.kint.2018.05.023","article-title":"Targeted inhibition of the type 2 cannabinoid receptor is a novel approach to reduce renal fibrosis","volume":"94","author":"Zhou","year":"2018","journal-title":"Kidney Int."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820303099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820303099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:05:34Z","timestamp":1758438334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390820303099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":54,"alternative-id":["S0028390820303099"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108241","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Xie2-64, a novel CB2 receptor inverse agonist, reduces cocaine abuse-related behaviors in rodents","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108241","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108241"}}